Scancell Holdings plc (AIM:SCLP)
London · Delayed Price · Currency is GBP · Price in GBX 9.33
-0.03 (-0.27%)
Oct 15, 2026, 2:34 PM GMT
Scancell Holdings Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
60
Market Cap
113.04M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2026 | - | - | - |
| Apr 30, 2025 | 4.71M | - | - |
| Apr 30, 2024 | - | - | - |
| Apr 30, 2023 | 5.27M | - | - |
| Apr 30, 2022 | - | - | - |
| Apr 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bioventix | 12.54M |
| PureTech Health | 4.80M |
| Ondine Biomedical | 1.53M |
| Faron Pharmaceuticals Oy | 1.14M |
| Arecor Therapeutics | 890.00K |
| 4basebio | 781.00K |
| Avacta Group | 113.00K |
| ImmuPharma | -69.96K |
Scancell Holdings News
- 6 days ago - Scancell FY26 Loss Widens; ISCIB1+ Phase 2 SCOPE Data Due In 2027 - Nasdaq
- 6 days ago - Scancell Holdings Annual report: H2 2026 - Filings
- 21 days ago - Scancell Secures Up To $25 Mln Debt Facility To Fund ISCIB1+ Phase 3 - Nasdaq
- 4 weeks ago - Scancell Holdings Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 1 month ago - Scancell Holdings Slides: Corporate presentation - Filings
- 5 months ago - Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study - GlobeNewsWire
- 8 months ago - Scancell Holdings Earnings Call Transcript: H1 2026 - Transcripts
- 8 months ago - Scancell Holdings Quarterly report: H1 2026 - Filings